Clinical Trial Update: Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ICP-723 in patients with NTRK fusion-positive advanced solid tumors or NTRK fusion-positive central nervous system tumors; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Fusion-positive Central Nervous System Tumors
• Ntrk Fusion-positive Solid Tumors

Drugs mentioned

• ICP-723

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion | Phase 1, Phase 2 | Status: RECRUITING